<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05007535</url>
  </required_header>
  <id_info>
    <org_study_id>SPECTRUM</org_study_id>
    <nct_id>NCT05007535</nct_id>
  </id_info>
  <brief_title>Tissue Characterization and Primary Percutaneous Coronary Intervention Guidance Using Intravascular Ultrasound</brief_title>
  <acronym>SPECTRUM</acronym>
  <official_title>Tissue Characterization and Primary Percutaneous Coronary Intervention Guidance Using Intravascular Ultrasound</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Acist Medical Systems</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>MicroPort CRM</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective, single arm, observational cohort study is designed to assess the safety and&#xD;
      efficacy of (high-definition) intravascular ultrasound (HD-IVUS) as guidance for primary&#xD;
      percutaneous coronary intervention (PCI) and to assess culprit lesion plaque characteristics&#xD;
      and thrombus morphology in patients with ST-elevation myocardial infarction (STEMI).&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
        -  To assess clinical outcomes after IVUS-guided primary PCI in STEMI patients.&#xD;
&#xD;
        -  To assess IVUS-guided optimization in STEMI patients.&#xD;
&#xD;
        -  To assess culprit lesion plaque characteristics in STEMI patients with HD-IVUS.&#xD;
&#xD;
        -  To assess and quantify thrombus in STEMI patients with HD-IVUS.&#xD;
&#xD;
        -  To explore HD-IVUS derived predictors for clinically relevant aspiration thrombectomy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The SPECTRUM study is an investigator-initiated, single-center, prospective, single arm,&#xD;
      observational cohort study investigating the safety and efficacy of (HD)-IVUS as guidance for&#xD;
      primary PCI in 200 patients with STEMI. This study enables the assessment of culprit lesion&#xD;
      plaque characteristics and thrombus morphology with a 40-60 MHz HD-IVUS catheter.&#xD;
&#xD;
      All study patients will have a protocolized pre-intervention IVUS pullback directly after&#xD;
      recanalization (so before any lesion preparation, i.e. balloon dilatation, aspiration&#xD;
      thrombectomy or stent placement) and a post-intervention IVUS pullback. Subsequently, if&#xD;
      IVUS-guided optimization is performed, a final pullback is highly recommended and considered&#xD;
      as the post-optimization IVUS pullback.&#xD;
&#xD;
      The primary study outcomes are target vessel failure at 12 months and incidence of&#xD;
      IVUS-guided optimization. More information on outcome measures is provided in the section&#xD;
      below.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 10, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Target Vessel Failure (TVF)</measure>
    <time_frame>12 Months</time_frame>
    <description>A composite of cardiac death, target vessel myocardial infarction and clinically driven target vessel revascularization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IVUS-guided optimization</measure>
    <time_frame>Procedural</time_frame>
    <description>Incidence of IVUS-guided additional balloon dilatation or stent placement after angiographically successful PCI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TVF</measure>
    <time_frame>30 Days</time_frame>
    <description>A composite of cardiac death, target vessel myocardial infarction and clinically driven target vessel revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiovascular Events (MACE)</measure>
    <time_frame>30 Days</time_frame>
    <description>A composite of all-cause mortality, any myocardial infarction and repeat revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiovascular Events (MACE)</measure>
    <time_frame>12 Months</time_frame>
    <description>A composite of all-cause mortality, any myocardial infarction and repeat revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual Components of TVF and MACE</measure>
    <time_frame>30 Days</time_frame>
    <description>Individual components of the composite endpoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual Components of TVF and MACE</measure>
    <time_frame>12 months</time_frame>
    <description>Individual components of the composite endpoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Intraprocedural Complications</measure>
    <time_frame>Procedural</time_frame>
    <description>Including type C-F dissections, perforations, slow flow or no-reflow, major side branch occlusion (&gt; 2 mm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic Endpoints</measure>
    <time_frame>Procedural</time_frame>
    <description>Including final TIMI flow and final myocardial blush grade</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IVUS endpoints (continuous)</measure>
    <time_frame>Procedural</time_frame>
    <description>At least the following continuous variables will be assessed for the first 100 patients with sufficient HD-IVUS pullbacks:&#xD;
Minimal lumen area&#xD;
Thrombus containing frames&#xD;
Thrombus maximum angle&#xD;
Minimal stent area&#xD;
Structured analysis of the HD-IVUS pullbacks will be performed with dedicated invasive imaging analysis software.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IVUS endpoints (categorical)</measure>
    <time_frame>Procedural</time_frame>
    <description>At least the following categorical variables will be assessed for the first 100 patients with sufficient HD-IVUS pullbacks:&#xD;
Plaque rupture&#xD;
Convex calcium (nodule)&#xD;
Thrombus type&#xD;
Plaque type&#xD;
Thrombus protrusion&#xD;
Underexpansion&#xD;
Edge dissection&#xD;
Hematoma&#xD;
High plaque burden at stent edges&#xD;
Residual focal lesion&#xD;
Malapposition&#xD;
Structured analysis of the HD-IVUS pullbacks will be performed with dedicated invasive imaging analysis software.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>ST Elevation Myocardial Infarction</condition>
  <condition>Acute Myocardial Infarction</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Percutaneous Coronary Intervention</condition>
  <condition>Intravascular Ultrasound</condition>
  <condition>Thrombus</condition>
  <arm_group>
    <arm_group_label>HD-IVUS-guided primary PCI</arm_group_label>
    <description>Prospective, single arm, observational</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients presenting with ST-elevation myocardial infarction eligible for primary&#xD;
        percutaneous coronary intervention.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Native coronary artery culprit lesion, angiographically&#xD;
&#xD;
          -  Culprit vessel reference diameter â‰¥ 2.25 mm, angiographically&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cardiogenic shock&#xD;
&#xD;
          -  Presentation &gt; 12 hours after symptom onset&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joost Daemen, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus MC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joost Daemen, MD PhD</last_name>
    <phone>+31 (0)10 70 352 60</phone>
    <email>j.daemen@erasmusmc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Frederik Groenland, MD</last_name>
    <phone>+31 (0)10 70 388 96</phone>
    <email>f.groenland@erasmusmc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Erasmus University Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joost Daemen, MD PhD</last_name>
      <phone>+31(0)107035260</phone>
      <email>j.daemen@erasmusmc.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 21, 2021</study_first_submitted>
  <study_first_submitted_qc>August 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2021</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasmus Medical Center</investigator_affiliation>
    <investigator_full_name>Joost Daemen</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Invasive Coronary Imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

